Literature DB >> 9108192

Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine.

T Carlsson, J Struve.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9108192     DOI： 10.1007/bf02113594

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  5 in total

1.  Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine.

Authors:  J Struve; B Aronsson; B Frenning; M Forsgren; O Weiland
Journal:  Scand J Infect Dis       Date:  1994

Review 2.  Vaccine adjuvancy: a new potential area of development for GM-CSF.

Authors:  M Taglietti
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

3.  Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination.

Authors:  S C Meuer; H Dumann; K H Meyer zum Büschenfelde; H Köhler
Journal:  Lancet       Date:  1989-01-07       Impact factor: 79.321

Review 4.  Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant.

Authors:  T Jones; A Stern; R Lin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

5.  Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine.

Authors:  P Jungers; P Devillier; H Salomon; J E Cerisier; A M Courouce
Journal:  Lancet       Date:  1994-09-24       Impact factor: 79.321
  5 in total
  3 in total

1.  A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus.

Authors:  Celestine N Wanjalla; Elizabeth F Goldstein; Christoph Wirblich; Matthias J Schnell
Journal:  Virology       Date:  2012-02-16       Impact factor: 3.616

2.  MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.

Authors:  P Mukherjee; L B Pathangey; J B Bradley; T L Tinder; G D Basu; E T Akporiaye; S J Gendler
Journal:  Vaccine       Date:  2006-11-16       Impact factor: 3.641

3.  Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection.

Authors:  Pierre Antoine Brown; Jonathan B Angel
Journal:  J Immune Based Ther Vaccines       Date:  2005-05-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.